Wonlim Q1 2026: Operating profit 1.22 billion won driven by medical segment, dividend increased to 460 won per share
Consolidated revenue 20.7bn won, operating profit 1.22bn won, net profit attributable to parent 0.67bn won (op profit -21% YoY, net -19%). Medical segment op profit 1.5bn won (+55%) drove growth; packaging segment recorded op loss of 0.68bn won (vs -0.08bn won prior).
Dividend increased to 460 won per share (from 400 won, +15%), total payout 0.95bn won.
Debt ratio 21.9% (up from 19.3% at year-end) but still healthy; credit rating maintained at BBB.
Exposure to JPY-denominated borrowings (approx. 5.3bn won), FX loss of 0.2bn won recognized. Three pending lawsuits deemed immaterial.